125 related articles for article (PubMed ID: 22440948)
1. Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices.
Négrier S
Oncology; 2012; 82(4):189-96. PubMed ID: 22440948
[TBL] [Abstract][Full Text] [Related]
2. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
Kirkali Z
BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
[TBL] [Abstract][Full Text] [Related]
3. New perspectives in the treatment of metastatic renal cell carcinoma.
Barrière J; Hoch B; Ferrero JM
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727
[TBL] [Abstract][Full Text] [Related]
4. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C
BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050
[TBL] [Abstract][Full Text] [Related]
5. Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan.
Wada Y; Takahashi W; Kawano Y; Eto M
Int J Urol; 2012 Apr; 19(4):284-95. PubMed ID: 22452375
[TBL] [Abstract][Full Text] [Related]
6. Management of metastatic renal cell carcinoma in the era of targeted therapies.
Webber K; Cooper A; Kleiven H; Yip D; Goldstein D
Intern Med J; 2011 Aug; 41(8):594-605. PubMed ID: 21627746
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.
Bex A; Gore M; Mulders P; Sternberg CN
BJU Int; 2012 Nov; 110(9):1289-300. PubMed ID: 22624610
[TBL] [Abstract][Full Text] [Related]
8. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Bellmunt J; Fishman M; Eisen T; Quinn D
Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
[TBL] [Abstract][Full Text] [Related]
9. [Adverse event profile of new targeted agents for renal cell carcinoma].
Nozawa M; Uemura H
Hinyokika Kiyo; 2012 Nov; 58(11):655-7. PubMed ID: 23254796
[TBL] [Abstract][Full Text] [Related]
10. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
[TBL] [Abstract][Full Text] [Related]
11. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
Wright I; Kapoor A
Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment.
Carles J; Chirivella I; Climent MA; Gallardo E; González del Alba A; Maroto JP; Mellado B; García del Muro FX
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S3-9. PubMed ID: 22689342
[TBL] [Abstract][Full Text] [Related]
13. Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma.
Schmidinger M; Bergler-Klein J
Int J Urol; 2012 Sep; 19(9):796-804. PubMed ID: 22583077
[TBL] [Abstract][Full Text] [Related]
14. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
15. [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
Tomita Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):907-10. PubMed ID: 21677480
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
17. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy.
You D; Jeong IG; Ahn JH; Lee DH; Lee JL; Hong JH; Ahn H; Kim CS
J Urol; 2011 Jan; 185(1):54-9. PubMed ID: 21074811
[TBL] [Abstract][Full Text] [Related]
18. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
[TBL] [Abstract][Full Text] [Related]
19. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
Leroy X; Edeline J; Rioux-Leclercq N
Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
[TBL] [Abstract][Full Text] [Related]
20. Sequential use of targeted agents in the treatment of renal cell carcinoma.
Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
